Biontech SE (BNTX) FinancialsBNTXFinancialBiontech SE

Biontech SE (BNTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Collaboration Revenue, accounting for 78.0% of total sales, equivalent to €32.59M. Other significant revenue streams include Biotech Business Unit - Manufacturing and Biotech Business Unit - Clinical. Understanding this composition is critical for investors evaluating how BNTX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Biontech SE maintains a gross margin of 8.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -902.75%, while the net margin is -777.27%. These profitability ratios, combined with a Return on Equity (ROE) of -9.30%, provide a clear picture of how effectively BNTX converts its operational activities into shareholder value.

In the context of the broader market, BNTX competes directly with industry leaders such as ZLAB and UTHR. With a market capitalization of $25.64B, it holds a leading position in the sector. When comparing efficiency, BNTX's gross margin of 8.14% stands against ZLAB's 60.25% and UTHR's 87.30%. Such benchmarking helps identify whether Biontech SE is trading at a premium or discount relative to its financial performance.

Biontech's recent financial performance shows a significant decline in revenue and net income. For Q2 2026, the revenue was only €105.6 million, a 59% decrease from the previous quarter. The gross margin has also dropped sharply to 8.14% in Q2 2026, down from 88.82% in Q3 2024, indicating severe financial strain.